National Institutes of Health Clinical Center (CC)

nih.gov

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

368

Capped at 5,000

Active

34

Phase 3

7

Total enrollment

30,691,686

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
filgrastim8
Dexamethasone2
Endotoxin2
Mycophenolate Mofetil1
Tacrolimus1
Post-Transplant Cyclophosphamide1
Briquilimab1
Spironolactone1
cyclophosphamide14
Fludarabine3
[18F]-Fluorocellobiose1

Next readouts

  • 2025-10-16
  • 2026-12-31
  • 2027-06-30
  • 2029-06-30
  • 2032-01-01

Top conditions

  • Healthy33
  • Unspecified Adult Solid Tumor, Protocol Specific19
  • Lymphoma17
  • Liver Cancer13
  • Melanoma (Skin)12
  • Healthy Volunteers12
  • Breast Cancer11
  • Kidney Cancer10

Frequently asked questions about National Institutes of Health Clinical Center (CC)

How many clinical trials does National Institutes of Health Clinical Center (CC) have on ClinicalTrials.gov?
National Institutes of Health Clinical Center (CC) is listed as the lead sponsor on 368 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
How many of National Institutes of Health Clinical Center (CC)'s trials are in Phase 3?
7 of National Institutes of Health Clinical Center (CC)'s trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does National Institutes of Health Clinical Center (CC) focus on?
National Institutes of Health Clinical Center (CC)'s most-studied conditions on ClinicalTrials.gov are Healthy, Unspecified Adult Solid Tumor, Protocol Specific, Lymphoma, Liver Cancer, Melanoma (Skin).
When are National Institutes of Health Clinical Center (CC)'s next clinical trial readouts?
National Institutes of Health Clinical Center (CC) has 5 upcoming primary-completion readouts tracked here; the soonest is “Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency”, expected around 2025-10-16.